Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06194448 · ClinicalTrials.gov registry record · Phase 2

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

A Phase 2 study of Lung Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 2
Development phase
76
Enrollment target
20
Study locations

NCT06194448 is a Phase 2 study of Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 76 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06194448, a Phase 2 study of Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
76 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).

Conditions Studied

Lung Cancer

Interventions

  • DRUG Osimertinib
  • DRUG Cisplatin or Carboplatin; Pemetrexed or Paclitaxel
  • DRUG Radiation

Study Locations (20)

Other

  • Research Site - Beijing
  • Research Site - Changsha
  • Research Site - Guangzhou
  • Research Site - Hangzhou
  • Research Site - Harbin
  • Research Site - Hefei
  • Research Site - Jinan
  • Research Site - Nanning
  • Research Site - Shanghai
  • Research Site - Tianjin
  • Research Site - Wuhan
  • Research Site - Wuhan
  • Research Site - Zhengzhou
  • Research Site - Haifa
  • Research Site - Jerusalem
  • Research Site - Tel Aviv
  • Research Site - Cheongju-si
  • Research Site - Seongnam-si

California

  • Research Site - La Jolla
  • Research Site - Palo Alto

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2024-04-21
Est. Completion 2027-07-07
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06194448

The ClinicalTrials.gov registry entry for NCT06194448 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Osimertinib is the first listed.

NCT06194448 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, California.

Frequently Asked Questions

What is clinical trial NCT06194448 about?

NCT06194448 is a clinical study titled "To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations". The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).

What is the current status of trial NCT06194448?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2024-04-21. Estimated completion is 2027-07-07.

What conditions does trial NCT06194448 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT06194448?

The interventions under investigation include: Osimertinib (DRUG), Cisplatin or Carboplatin; Pemetrexed or Paclitaxel (DRUG), Radiation (DRUG).

Who is sponsoring clinical trial NCT06194448?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06194448 being conducted?

This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.